Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

NCT04140487 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

97

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Acute Myeloid Leukemia
Recurrent Chronic Myelomonocytic Leukemia
Recurrent Myelodysplastic/Myeloproliferative Neoplasm
Refractory Acute Myeloid Leukemia
Refractory Chronic Myelomonocytic Leukemia
Refractory Myelodysplastic/Myeloproliferative Neoplasm

Interventions

DRUG: Azacitidine
DRUG: Gilteritinib
DRUG: Venetoclax

Sponsor

M.D. Anderson Cancer Center